The structural design of vaccines focuses on understanding and manipulating the three-dimensional structure of pathogens or their components to create more effective vaccines. By analyzing the structure of proteins or antigens, researchers can determine which parts of the pathogen are most likely to trigger a strong immune response. This understanding is essential for designing vaccines that can precisely target these key structures, leading to a more effective and specific immune response. Advanced technologies such as cryo-electron microscopy and X-ray crystallography have allowed scientists to visualize the atomic structure of viral proteins in unprecedented detail. This has led to breakthroughs in the design of vaccines that target specific components of pathogens, such as spike proteins in the case of SARS-CoV-2. Structural vaccinology also helps in designing subunit vaccines, which contain only parts of a pathogen, reducing the risk of adverse reactions while maintaining efficacy.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States